Supported by GE Healthcare

Gadolinium-based contrast agents (GBCAs) differ in structure and ionicity which, in turn affects their stability and safety profiles. The more stable agents are associated with a lower risk of nephrogenic systemic fibrosis (NSF) and less Gd deposition in brain, bone, and other tissues. Several patient populations are considered vulnerable to Gd exposure, including children, the elderly, the renally impaired, and those that require repeat MRI exams.

In these cases, GBCA utilization should be limited to studies where the results contribute significantly to the diagnosis and/or patient management.

In the following webinar and corresponding monograph, Lawrence N. Tanenbaum, MD, FACR and Donna Roberts, MD share case examples including MRI applications and considerations for understanding at risk adult and pediatric patient populations when performing Neuro MRI.

Supported by GE Healthcare

In this Expert Forum, Lawrence Tanenbaum, MD, FACR and Suzie Bash, MD review considerations for optimizing contrast-enhanced MRI in neuroimaging, extending from patient tolerance to standardizing procedures. Following the presentation questions from the audience were addressed in a moderated Q&A session.

Supported by GE Healthcare

In this Expert Forum, Dr. Lawrence Tanenbaum, MD, FACR, will review the classification of Gadolinium MR contrast agents according to their molecular structure, ionicity, and stability. The impact of these properties and supporting clinical data for safety considerations in choosing an agent will be discussed with the goal of providing insight that can be applied in everyday clinical practice. Following the presentation questions from the audience were addressed in a moderated Q&A session.